Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value

Keith M. Skubitz, Anne H. Blaes, Suma H. Konety, Gary S. Francis

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Fingerprint

Dive into the research topics of 'Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds